Introduction
Characterization of the surface phenotypes of hematopoietic stem cells (HSCs) and development of techniques for their purification are important subjects in stem cell transplantation and gene therapy. Transplantation of purified human HSCs that are free of T lymphocytes could minimize graft-versushost disease in allogeneic transplantation. In autologous situations, transplantation of HSCs that are free of tumor cells may reduce the risk of recurrence of malignancies.
For many years, CD34 and CD38 have been regarded as important markers for HSC. It was generally accepted that human HSCs and primitive progenitors are CD34
however, recent studies of murine stem cells caused controversies about surface phenotypes of HSCs. It was documented that the majority of adult murine HSCs are CD34 − . [2] [3] [4] In our laboratory, we observed that the developmental change of CD34 expression from positive to negative state takes place between 7 and 10 weeks of age for most of murine HSCs. 5 We also discovered that CD34 expression by adult stem cells is influenced by the activation state of the HSCs. 2 Regarding stem cell CD38 expression, investigators in four different laboratories including ours reported that HSCs in yolk sac, fetal liver and adult mouse bone marrow express CD38. [6] [7] [8] [9] We demonstrated that activation of adult murine HSCs causes reversible changes in CD38 expression. 6 Unknown has been the state of CD38 expression by HSCs of newborn or juvenile mice. This question has significant clinical relevance because cord blood cells recently have emerged as an important source for stem cell transplantation. 10 In this paper, we used a mouse transplantation model to examine CD38 expression by HSCs in the bone marrow of newborn and 5-week-old mice. Cell preparation C57BL/6-Ly-5.1 mice originally obtained from Jackson Laboratories (Bar Harbor, ME, USA) and bred in the Animal Research Facility of The Veterans Affairs Medical Center were used as newborn and juvenile donors. Ten to 14-week-old C57BL/6-Ly-5.2 female mice (Charles River Laboratories, Raleigh, NC, USA) were used as irradiated recipients and as the source for radioprotective cells. In some experiments, the juvenile donor mice were treated with an intravenous injection of 5-fluorouracil (5-FU) at 100 mg/kg body weight 48 h before death. Bone marrow cells from Ly-5.1 mice were flushed from femurs and tibiae, pooled, and washed twice with phosphate-buffered saline containing 0.1% bovine serum albumin. The samples were then made into single cell suspension by repeated pipetting and filtering through 40 m nylon mesh. The cells with densities ranging from 1.063 to 1.077 g/ml were collected by gradient separation using Nycodenz (Accurate Chemical and Scientific Corp, Westbury, NY, USA). The resulting mononuclear cells (MNCs) were stained with FITC-conjugated anti-CD38 and biotin-conjugated anti-CD34 followed by streptavidin PE. After addition of propidium iodide at a concentration of 1 g/ml, the cells were washed twice, resuspended in phosphate-buffered saline containing 0.1% bovine serum albumin and kept on ice until cell sorting. Fluorescence-activated cell sorting (FACS) was performed on a FACS Vantage (Becton Dickinson, San Jose, CA, USA), with appropriate isotype-matched controls.
Materials and methods

Monoclonal antibodies
Hematopoietic reconstitution
Ly-5.2 mice were administered a single 950-cGy dose of total body irradiation using a 4 × 10 6 V linear accelerator. Sorted Ly-5.1 cells were injected into the tail vein of the irradiated Ly-5.2 mice along with 2 × 10 5 bone marrow cells from adult Ly-5.2 mice as radioprotective cells. In all experiments, the number of cells transplanted reflected the ratios of cells in the sorting windows. For analysis of engraftment, peripheral blood was obtained from the retro-orbital plexus using heparincoated micropipets (Drummond Scientific, Broomall, PA, USA). The samples were stained with FITC-conjugated antiLy-5.1 and red blood cells were lysed using FACS Lysing Solution (Becton Dickinson). Analysis for donor-derived cells was carried out on a FACS Calibur (Becton Dickinson). Donor (Ly-5.1) cells in granulocyte and monocyte/macrophage, T-cell, and B-cell lineages were analyzed by staining with PE-conjugated anti-Gr-1 and PE-conjugated anti-Mac-1, PE-conjugated anti-Thy-1.2 and PE-conjugated anti-B220, respectively.
Data presentation and statistical analysis
The number of repopulating units (RU) in each test samples was calculated from the percentage donor cells engrafted, D, according to the formula: RU = competitor RU × D/(100−D), described by Harrison et al. 11 After donor RU were calculated relative to RU of 2 × 10 5 bone marrow cells in each recipients, mean ± s.d. percentages of RU in the CD38
− and CD38 + cell populations were computed. Levels of significance were determined using the Student's t-test.
Results
CD38 expression by HSCs of newborn mice
Earlier, we and other investigators documented that all HSCs of 5-week-old and younger mice are CD34 + . 5, 12 We therefore tested the engraftment capabilities of CD38 − and CD38 + subpopulations of CD34
+ bone marrow cells of newborn mice using the FACS regions shown in 
CD38 expression by HSCs of 5-week-old mice
Next, we analyzed the CD38 expression by long-term engrafting cells of 5-week-old mice. Because we and other investigators documented that all bone marrow HSCs of 5-week-old and younger mice are CD34 
CD38 expression by HSCs of 5-FU-treated 5-week-old mice
We have shown in previous studies that activated adult HSCs were CD38 − . 6 To determine whether there are similar effects on stem cells in 5-week-old mice, we tested CD38 expression by HSCs of 5-week-old mice following 5-FU injection. Because the effects of 5-FU injection on the expression of CD34 by HSCs in 5-week-old mice are not known, we separated bone marrow cells on the basis of CD38 expression Leukemia alone. The sorting regions are presented in Figure 5 . Since the ratio of the CD38 − (R5) to CD38 + (R6) cell populations in the bone marrow from 5-FU-treated mice was 1:1, we transplanted 3 × 10 5 cells of both populations per mouse. The average engraftment levels of the recipients transplanted with CD38 − cells and CD38 + cells were 10.4 ± 9.0% and 43.8 ± 14.7% at 6 months post-transplantation, respectively ( Figure 6) . These values were different at P Ͻ 0.002. Again, multilineage engraftment was seen in all recipient mice.
Discussion
In this report, we studied CD38 expression by HSCs in the bone marrow of newborn and 5-week-old mice. The results clearly demonstrated that all HSCs of newborn mice and the majority of HSCs in the bone marrow of 5-week-old mice are CD38 − . We also observed that CD38 + marrow cells from 5-FU-treated 5-week-old mice show higher engraftment levels than CD38
− cells. The latter observation indicated that activation of juvenile HSCs enhances CD38 expression. This direction of changes is opposite to that of the changes seen in adult HSCs. Based on these observations, it was concluded that CD38 is expressed by HSCs throughout murine ontogeny. 8 However, our results clearly indicated that all HSCs of newborn mice and the majority of HSCs in the bone marrow of 5-week-old + to CD38 − state must take place between 14.5 dpc and the perinatal period. Earlier, we documented that a minority of adult HSCs are CD38 − . 6 It appears that the second ontogenetic conversion from CD38 − to CD38 + stem cells begins before the age of 5 weeks. In earlier reports from our laboratory, 2,5 we described that CD34, another important surface molecule of HSCs, is also under developmental control and affected by the activation state of HSCs. HSCs in fetal and juvenile mice are CD34 + . 5 The change of HSC CD34 expression from the positive to negative state takes place between 7 and 10 weeks of age for the majority of murine HSCs. 5 The physiological significance of the developmental change in stem cell CD34 expression is unclear because genetically engineered CD34-null mice show normal hematopoiesis in vivo. 13 The physiological significance of the bidirectional ontogenic changes in CD38 expression of HSCs we described here is also unknown. CD38 is an ectoenzyme that utilizes NAD + (nicontinamide adenine dinucleotide) and is expressed by many hematopoietic cells.
14 However, CD38-null mice exhibited a normal compartment of all hematopoietic lineages, 15 indicating that CD38 is dispensable for lymphohematopoiesis. It is possible that the absence of stem cell abnormalities seen in the CD38-and CD34-null mice may be due to the presence of other molecules with functional redundancy. Both CD38 and CD34 are considered to be adhesion molecules. 13, 14 The fact that they are ontologically regulated may indicate an important function that has yet to be elucidated.
Murine CD38 cDNA shows 70% sequence homology with that of human CD38. 16 Thus, our observations in a mouse model may possess implications for CD38 expression by HSCs from human umbilical cord blood and the bone marrow of young children under steady-state and pathological conditions.
